Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: ASE
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

NRT:AU

0.1100 AUD 0.0050 4.35%

As of 00:10:59 ET on 01/28/2015.

Snapshot for Novogen Ltd (NRT)

Open: 0.1100 Day's Range: 0.1100 - 0.1150 Volume: 812,917
Previous Close: 0.1150 52wk Range: 0.0810 - 0.2700 1-Yr Rtn: -43.59%

Stock Chart for NRT

No chart data available.
  • NRT:AU 0.1100
  • 1D
  • 1M
  • 1Y
0.1150
Interactive NRT Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NRT

Current P/E Ratio (ttm) -
Estimated P/E(06/2015) -
Relative P/E vs. AS51 -
Earnings Per Share (AUD) (ttm) -0.0504
Est. EPS (AUD) (06/2015) -
Est. PEG Ratio -
Market Cap (M AUD) 27.12
Shares Outstanding (M) 246.59
30 Day Average Volume 5,781,350
Price/Book (mrq) 12.2728
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/02/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NRT

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)

Company Profile & Key Executives for NRT

Novogen Limited is a medical services company which develops and markets pharmaceutical products in Australia. The Company conducts clinical trials on medications which promote the prevention and treatment of common cancers and the reversal of immune depression. The Company also develops dietary supplements, hormonal imbalance drugs, anti-inflammatory and cardiovascular drugs.

Graham Edmund KellyChairman/CEO/Exec Dir/FounderDavid BrownChief Scientific Officer
Justine StehnDir:ATM ProgramStephen PalmerDir:Degenerative Disease Program
More Company Profile & Key Executives for NRT

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil